Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05169957 · ClinicalTrials.gov registry record · Phase 1
Hepatic Ablation of Melanoma Metastases to Enhance Immunotherapy Response, a Phase I Clinical Trial (HAMMER I)
A Phase 1 study, sponsored by University of Michigan Rogel Cancer Center.
- Completed
- Registry status
- Phase 1
- Development phase
- 2
- Enrollment target
NCT05169957 is a Phase 1 study that has completed, run by University of Michigan Rogel Cancer Center. The registered enrollment target is 2 participants.
The verdict
NCT05169957, a Phase 1 study, has completed, sponsored by University of Michigan Rogel Cancer Center.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 2 participants
- Enrollment target
Study Summary
The primary purpose of this study is to determine the feasibility of liver stereotactic body radiation therapy (SBRT) given in combination with systemic therapy (ipilimumab and nivolumab) in adults with metastatic melanoma with liver metastases who are at significant risk of not benefiting from systemic therapy alone.
Interventions
- DRUG Nivolumab
- DRUG Ipilimumab
- PROCEDURE Stereotactic Body Radiation Therapy
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 2 participants |
| Start Date | 2022-08-09 |
| Est. Completion | 2024-07-17 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05169957
The ClinicalTrials.gov registry entry for NCT05169957 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 2 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Michigan Rogel Cancer Center, which has 292 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Nivolumab is the first listed.
NCT05169957 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT05169957 about?
NCT05169957 is a clinical study titled "Hepatic Ablation of Melanoma Metastases to Enhance Immunotherapy Response, a Phase I Clinical Trial (HAMMER I)". The primary purpose of this study is to determine the feasibility of liver stereotactic body radiation therapy (SBRT) given in combination with systemic therapy (ipilimumab and nivolumab) in adults with metastatic melanoma with liver metastases who are at significant risk of not benefiting from syst...
What is the current status of trial NCT05169957?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 2 participants. The study started on 2022-08-09. Estimated completion is 2024-07-17.
What interventions are being tested in trial NCT05169957?
The interventions under investigation include: Nivolumab (DRUG), Ipilimumab (DRUG), Stereotactic Body Radiation Therapy (PROCEDURE).
Who is sponsoring clinical trial NCT05169957?
This trial is sponsored by University of Michigan Rogel Cancer Center, which has 292 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.